PROCEPT BioRobotics Corporation Common Stock Q3 2025 Earnings Recap

PRCT Q3 2025 November 5, 2025

PROCEPT BioRobotics reported robust third quarter 2025 results, achieving $83.3 million in total revenue, a 43% year-over-year increase, driven by strong capital system sales. The company remains focused on enhancing procedure utilization and expanding market awareness for its innovative Aquablation therapy.

Earnings Per Share Beat

$-0.38 vs $-0.41 est.

+7.3% surprise

Revenue Miss

83327000 vs 93703790 est.

-11.1% surprise

Market Reaction

1-Day -9.74%

5-Day -11.65%

30-Day -9.54%

Key Takeaways

Total revenue reached $83.3 million, with U.S. sales contributing $73.9 million, showcasing solid growth amidst market scrutiny.
58 U.S. capital systems shipped in the quarter, indicating a stable pricing environment despite tightening capital budgets in large hospital systems.
Organizational changes aimed at improving commercial execution, including expedited new account launches and a sharpened focus on international markets.
Potential expansion into prostate cancer treatment, supported by the ongoing WATER IV clinical trial, highlights the long-term growth opportunities beyond BPH.
Commitment to enhancing patient awareness and accelerating therapy adoption, leveraging new talent within leadership.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit PRCT on AllInvestView.